Clinical trials: Patients with Advanced Solid Tumors
Solid Tumor
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid…
- Trial name
- NCT05907980
- Testing
- ROSE12, Atezolizumab, Pembrolizumab
- Where
- 14 sites in United States, Japan
- Volunteers
- 209 people
- Sponsor
- Chugai Pharmaceutical
Advanced Solid Tumours
Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer
The purpose of this study is to determine whether AZD0156 is safe, what is the best dose to give, and how it is processed by the body when given alone or in combination with other agents.
- Trial name
- AToM (NCT02588105)
- Testing
- AZD0156, Olaparib, irinotecan
- Where
- 5 sites in United States, South Korea and 2 more
- Volunteers
- 84 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
XTX301 in Patients With Advanced Solid Tumors
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
- Trial name
- NCT05684965
- Testing
- XTX301
- Where
- 12 sites in United States
- Volunteers
- 358 people
- Sponsor
- Xilio Development, Inc.
Breast Cancer, Solid Tumor
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in…
- Trial name
- NCT06503783
- Testing
- BL-M17D1
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Mesothelioma
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated…
- Trial name
- NCT04857372
- Testing
- IAG933
- Where
- 16 sites in United States, Australia and 9 more
- Volunteers
- 137 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors Cancer
First-In-Human Study of KHN922 for Injection
A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors
- Trial name
- NCT07514975
- Testing
- KHN922 for injection
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Advanced Solid Tumors
Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours
The primary objective of this study was to determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered orally, once daily, to patients with advanced solid…
- Trial name
- NCT00692354
- Testing
- CHR-2797 (tosedostat)
- Volunteers
- 41 people
- Sponsor
- Chroma Therapeutics
Esophageal Neoplasms, Hepatocellular Carcinoma
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.
- Conditions
- Esophageal Neoplasms, Hepatocellular Carcinoma, Colorectal Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00057395
- Testing
- Aroplatin (Liposomal NDDP, L-NDDP)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Aronex Pharmaceuticals
Advanced Solid Tumors
Phase 1 Trial of KH801
KH801 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Or 0.9% sodium chloride Injection. This study is expected to include a total of approximately 17-42 participants.
- Trial name
- NCT06364501
- Testing
- KH801
- Where
- 4 sites in China
- Volunteers
- 17 people
- Sponsor
- Beijing Kanghong Biopharmaceutical Co., Ltd.
Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer
A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors
1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies
- Conditions
- Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02990481
- Testing
- TRK-950
- Where
- 3 sites in United States, France
- Volunteers
- 38 people
- Sponsor
- Toray Industries, Inc
Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3
This is a Phase 1a/1b, multicenter, open-label, first-in-human (FIH) study with MX006 treatment in patients with selected tumor types known to express B7-H3.
- Trial name
- NCT07807241
- Testing
- MX006
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 120 people
- Sponsor
- Myricx Pharma Limited
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Advanced Solid Tumor, Advanced Breast Cancer
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in…
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
- Trial name
- NCT06120283
- Testing
- BGB-43395, Fulvestrant, Letrozole
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 433 people
- Sponsor
- BeOne Medicines
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Solid Tumor
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
This is a FIH, open-label, Phase I dose-escalation study of ADG116 in subjects with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.
- Trial name
- NCT04111445
- Testing
- ADG116
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Adagene Inc
Solid Tumor, Gastric Cancer
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT04400383
- Testing
- AB011 Injection
- Where
- 12 sites in China
- Volunteers
- 62 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Locally Advanced or Metastatic Solid Tumors
Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors
Patients will be enrolled in two stages: Dose-escalation stage: Approximately 15-30 patients will be enrolled. Dose-expansion stage: 6-12 patients will be enrolled.
- Trial name
- NCT03478995
- Testing
- GX-I7
- Where
- 3 sites in South Korea
- Volunteers
- 35 people
- Sponsor
- Genexine, Inc.
Cancer
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
This is a Phase Ib, open-label, multiple-center, multiple-dose study designed to evaluate the pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies (including hepatocellular carcinoma and…
- Trial name
- NCT01546519
- Testing
- Vismodegib
- Where
- 5 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Solid Tumors
A Study of ZG005 in Patients With Advanced Solid Tumors
This is a multi-center, open-label, Phase 1/2 study of ZG005 for the treatment of subjects with advanced solid tumors, and consists of three stages: dose escalation and confirmation of MTD/recommended dose.
- Trial name
- NCT06233292
- Testing
- ZG005 Powder for Injection
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Tumors
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
- Trial name
- NCT02549937
- Testing
- surufatinib
- Where
- 12 sites in United States, Italy
- Volunteers
- 130 people
- Sponsor
- Hutchmed